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Pive-Year Follow-Up of the Argentine
andomized Trial of Coronary Angioplasty
ith Stenting Versus Coronary Bypass Surgery
n Patients With Multiple Vessel Disease (ERACI II)
lfredo E. Rodriguez, MD, PHD, FACC,* Julio Baldi, MD, PHD,* Carlos Fernández Pereira, MD,*
ose Navia, MD,* Máximo Rodriguez Alemparte, MD,* Alejandro Delacasa, MD,† Federico Vigo, MD,*
aniel Vogel, MD,* William O’Neill, MD, FACC,‡ Igor F. Palacios, MD, FACC,§ on behalf of the
RACI II Investigators
uenos Aires and Mar del Plata, Argentina; Royal Oak, Michigan; and Boston, Massachusetts
OBJECTIVES The purpose of the present study is to report the five-year follow-up results of the ERACI
II trial.
BACKGROUND Immediate and one-year follow-up results of the ERACI II study showed a prognosis
advantage of percutaneous coronary intervention (PCI) with stents over coronary artery
bypass grafting (CABG).
METHODS A total of 450 patients were randomly assigned to undergo either PCI (n  225); or CABG
(n  225). Only patients with multi-vessel disease were enrolled. Clinical follow-up during
five years was obtained in 92% of the total population after hospital discharge. The primary
end point of the study was to compare freedom from major adverse cardiovascular events
(MACE) at 30 days, 1 year, 3 years, and 5 years of follow-up.
RESULTS At five years of follow-up, patients initially treated with PCI had similar survival and freedom
from non-fatal acute myocardial infarction than those initially treated with CABG (92.8% vs.
88.4% and 97.3% vs. 94% respectively, p  0.16). Freedom from repeat revascularization
procedures (PCI/CABG) was significantly lower with PCI compared with CABG (71.5% vs.
92.4%, p  0.0002). Freedom from MACE was also significantly lower with PCI compared
with CABG (65.3% vs. 76.4%; p  0.013). At five years similar numbers of patients
randomized to each revascularization procedure were asymptomatic or with class I angina.
CONCLUSIONS At five years of follow-up, in the ERACI II study, there were no survival benefits from any
revascularization procedure; however patients initially treated with CABG had better freedom
from repeat revascularization procedures and from MACE. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.081582–8) © 2005 by the American College of Cardiology Foundation
c
r
w
c
m
m
E
o
v
t
A
i
r
C
d
p
M
D
l
moronary artery bypass grafting (CABG) and percutaneous
oronary intervention (PCI) are commonly used procedures
o treat patients with multiple coronary artery disease
CAD) requiring myocardial revascularization. In the past,
everal randomized comparisons between bypass surgery
nd coronary angioplasty were performed (1–9).
See page 589
These studies, performed in the pre-stent era, showed no
ignificant differences in mortality and non-fatal myocardial
nfarction (MI) between patients treated with surgery versus
CI. Surgery had an advantage only in treated diabetic
atients (7). More recently, in the stent era, new random-
zed comparison between percutaneous intervention and
ypass surgery has been done, and three multicenter clinical
rials have reported their short- and mid-term outcome
10–13). Thirty-day and one-year major adverse cardiovas-
From the *Otamendi Hospital, Buenos Aires; †Sanatorio Belgrano, Mar del Plata,
rgentina; ‡William Beaumont Hospital, Royal Oak, Michigan; and §Massachusetts
eneral Hospital, Boston, Massachusetts. The study was supported by an unrestricted
rant from COOK Inc. (Bloomington, Indiana).o
Manuscript received October 11, 2004; revised manuscript received December 13,
004, accepted December 20, 2004.ular events (MACE), including death, MI, stroke, and
epeat revascularization procedures with both techniques
ere recently published.
The 30-day and 1-year outcome of the first randomized
omparison between percutaneous interventions in the bare-
etal stent era and coronary bypass surgery in patients with
ultiple-vessel disease was published in this journal by the
RACI II investigators (11). The one-year follow-up data
f the four randomized trials of PCI using bare metal stents
ersus CABG (Stent or Surgery trial, Artery Revasculariza-
ion Therapies Study [ARTS], ERACI II, and Medicine,
ngioplasty, or Surgery Study [MASS] II) showed similar
ncidence in the combined death, non-fatal MI, and stroke
ate with both revascularization techniques (PCI 8.7% vs.
ABG 9.1%; p  NS). In the present study, we are
escribing the five-year clinical follow-up results of the
atients randomized in the ERACI II study.
ETHODS
etails of the ERACI II trial have been previously pub-
ished in this journal (11). This trial included patients with
ulti-vessel coronary artery disease and clinical indication
f myocardial revascularization. In these patients, completed
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August 16, 2005:582–8 Stents Versus CABG in Multi-Vessel Diseaseunctional revascularization could be achieved by either PCI
r coronary bypass surgery. A total of 5,619 patients
nderwent coronary angiography in the participating cen-
ers of the ERACI II between October 1996 and September
998 (11). Of this group, 2,759 patients had an indication
or revascularization, and of these, 1,076 patients met the
ntrance criteria for randomization. Of these 1,076 patients,
50 patients were randomized, and are the subject of this
tudy. Six hundred twenty-six patients with angiographic
nd clinical criteria for randomization were not randomized
ecause they refused or because of their referral physician
reference (335 patients had PCI and 291 had CABG).
he other 1,683 patients treated with either PCI or CABG
id not meet the randomization criteria and were included
n the registry. Angioplasty procedures were performed in
,396 of these patients because the following reasons:
ingle-vessel disease (67.5%), two-vessel disease (1.5%),
revious CABG (5%), acute MI (AMI) (10%), and previous
CI (16%). Of the 287 patients in the registry who
nderwent CABG, 16% were selected for a protocol of
inimal invasive surgery, 27% had significant main left
tenosis, 1.7% had previous CABG, 27% had poor left
entricular function, and 28.3% had multi-vessel disease not
menable to PCI. Patients were eligible for inclusion if they
ad severely limiting stable angina (Canadian class III/IV),
nstable angina according Braunwald criteria (11), or mild
ymptoms but with a large area of myocardium at risk
etermined by thallium scintigraphy. Coronary stent de-
loyment and surgical techniques were performed with
tandard methods as previously described (10–17). The
atients were required to have 50% stenosis in more than
ne major pericardial vessel and 70% in at least one of the
ajor epicardial vessels by visual estimation. The vessel
hould also be suitable for stent deployment. Patients with
nprotected severe left main stenosis could be included if
hey were amenable to a single stent procedure according to
he interventionalist’s point of view. Patients with post-
MI were also included.
Patients with poor left ventricular function (left ventric-
lar ejection fraction 35%), concomitant severe valvular
Abbreviations and Acronyms
AMI  acute myocardial infarction
ARTS  Artery Revascularization Therapies Study
CABG  coronary artery bypass grafting
CAD  coronary artery disease
ERACI II  Argentine Randomized Study: Coronary
Angioplasty with Stenting Versus Coronary
Bypass Surgery in Multi-Vessel Disease
LAD  left anterior descending
LIMA  left internal mammary artery graft
MACE  major adverse cardiovascular events
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplastyeart disease, evolving AMI (24 h), previous CABG, urevious percutaneous transluminal coronary angioplasty
PTCA) in the last year with predominant vessel occlusion
two or more), and/or limited life expectancy were excluded
rom the study.
tudy end points. The composite primary end point of the
tudy was the occurrence of combined MACE, defined as
eath, Q-wave MI, stroke, and need for repeat revascular-
zation procedures at 30 days, 1 year, 3 years, and 5 years of
ollow-up. Death included mortality from all causes.
Secondary end points included: angina status and func-
ional class at one, three, and five years of follow-up;
ompleteness of revascularization, determined by stress
hallium at one month; and follow-up cost and cost-
ffectiveness of both techniques. The major in-hospital
omplications and follow-up events (mortality, MI, stroke,
ngina, and the need of additional revascularization proce-
ures) were recorded. A trained staff was responsible for
ata collection of variables and clinical follow-up informa-
ion. Randomization of patients fulfilling the inclusion
riteria was performed by the coordinating center in 10-
atient blocks. A randomization sequence was developed so
hat an equal number of patients were assigned to each
reatment strategy at each center. Patients or their referring
hysician during the five years of follow-up were contacted
very six months by trained staff, using personal interviews,
etters, or telephone. At five years, clinical follow-up was
btained in 92% of hospital survivors.
The organization and analysis of the results of the study
ere conducted by a central coordinating executive commit-
ee. The study was monitored by a Safety and Data
onitoring Committee.
tatistics. The primary analysis of angiographic and clini-
al outcomes was based on the intention-to-treat principle.
The results are expressed as mean  standard deviation.
or comparison of the continuous variable between the two
reatment groups, the unpaired two-tailed Student t test was
sed. Comparison of categorical variables between the two
roups was performed with the chi-square and Fischer exact
est methods. Comparison of the composite clinical end
oint (MACE) was performed with the Kaplan-Meier and
og-rank tests (18). All tests were two-tailed, and a p value
f 0.05 was considered statistically significant. As previ-
usly reported, the power of the study to detect differences
uring the first 30 days was 90% (11).
ESULTS
atient population. The two randomized groups were
ell-matched for baseline demographic, clinical, and angio-
raphic characteristics (Table 1). The incidence of unstable
ngina IIb, IIIa, and C was high in the overall cohort of
atients (91.1%) and similar in PCI (92%) and CABG
91%). Post-AMI angina was present in 10% of the pa-
ients. In the registry, the incidence of patients with
nstable coronary syndromes was also high. Unstable angina
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Stents Versus CABG in Multi-Vessel Disease August 16, 2005:582–8as present in 61.3%, and the incidence of non–ST-
egment elevation MI was 12%.
Concomitant peripheral or vascular disease was present in
3% of the patients (27% in CABG arm). Glycoprotein IIb
nd IIIa inhibitors were used in 28% of the patients in the
CI group (Table 1). There were also no differences in the
ncidence of two- and three-vessel disease between the two
trategies of revascularization. Proximal left anterior de-
cending coronary artery (LAD) stenosis (before the take-
ff of the first diagonal branch) was present in 113 patients
andomized to PCI and in 117 patients randomized to
ABG. After randomization, and before the index proce-
ure was performed, 3 patients from the PCI group crossed
ver to CABG, whereas 16 patients from the CABG group
rossed over to PCI (1.4% vs. 7.6%, p  0.04). In the PCI
roup, at least 99% of the patients had one vessel success-
ully treated, and 80.5% of the patients had two vessels
uccessfully treated; whereas 91.5% of planned vessels were
uccessfully treated. Excluding those patients with chronic
otal occlusions, only 8.8% of the patients had severe
esidual stenosis in one major epicardial vessel after the PCI
rocedure. The number of chronic occlusions not attempted
y PCI, as we reported previously, was 23.4% (11). The
verall 448 lesions attempted in the PCI arm were treated
ith either 315 stents (Gianturco Rubin II design in 92% of
esions) or balloon angioplasty. Thus, in the stent arm, the
lanned vessels PCI strategy was successfully performed in
1.5% of the patients using 1.4 stent per patient. In the
urgical group, arterial conduits were used in 88.5% of the
atients.
nitial and one-year follow-up. As previously published
11), 30-day MACE were significantly lower with stent
herapy than with bypass surgery (3.6% vs. 12.3%, p 
.002). One-month mortality was also significantly lower
ith stent therapy (0.9% vs. 5.7%, p  0.013). Although
his study was not designed to assess hospital outcomes
able 1. Baseline Demographic, Clinical, and Angiographic
haracteristics: ERACI II (11)
PTCA (n  225) CABG (n  225)
ale 77.3% 81.4%
ge 62.4% 61.3%
ypertension 71% 70.5%
mokers 54.3% 49.5%
iabetic 17.3% 17.3%
igh cholesterol 62.5% 60.2%
revious infarction 28.5% 27.7%
besity 28.8% 23.5%
nstable II/III/C 92.1% 90.7%
eripheral disease 19.1% 26.6%
ouble vessel 40% 38%
hree vessel 54.7% 58%
eft main 5.3% 4%
ll p values not significant.
CABG  coronary artery bypass graft surgery; ERACI II  Argentina Random-
zed Study Coronary Angiopasty with Stenting Versus Coronary Bypass Surgery in
atients with Multiple Vessel Disease; PTCA  percutaneous transluminal coronary
ngioplasty.ccording to angina class, there was a trend toward a higher a0-day mortality rate in patients with unstable angina
reated with surgery. There were no hospital mortalities
ith surgery in patients with stable angina, whereas it
eached 5.6% and 7.9% in patients with unstable class II and
nstable class III or C. Compared with PCI, only surgically
reated patients with unstable class III or C angina have a
reater in-hospital mortality (p  0.06 in favor of PCI ).
wing to the above differences during the initial hospital
eriod with the two revascularization techniques, survival
uring the first year of follow-up was better with PCI
ompared with surgery (96.9% vs. 92.5%, p  0.017).
urvival with freedom from non-fatal MI was also better
ith PCI therapy than with surgery (97.7% vs. 93.7%, p 
.017). In contrast, despite the liberal use of stents, freedom
rom new revascularization procedures and incidence of
ngina were significantly better with bypass surgery. Hos-
ital and follow-up costs did not show any differences
etween the two revascularization techniques.
In the subgroup of diabetic patients included in the
andomization population (39 patients), there was a trend to
igher mortality in the PCI diabetic patients compared with
CI in non-diabetic patients (10% vs. 6.4%, p  0.663). In
ontrast, in the patients randomized to surgery, the five-year
ortality in the diabetic population was 10.2%, whereas it
as 11.8% in the non-diabetic population (p  0.637).
Surgical mortality was 2.1% in the 287 patients under-
oing surgical revascularization in the registry. These pa-
ients in the registry included those patients who were
ncluded in a protocol of minimally invasive surgery. They
ad left internal mammary artery graft (LIMA) to LAD,
ecause they had either single-vessel LAD disease, or
ecause they were candidates for hybrid procedures (LIMA
o LAD  PCI to right coronary artery or circumflex). In
ontrast, 30-day surgical mortality was 7.1% in the rest of
atients who underwent surgery in the registry. They
ncluded a cohort of patients with poor left ventricular
unction (n  77), patients with severe main left stenosis
n  77), patients with multi-vessel disease and lesions not
menable to PCI (n  81), and patients with previous
ardiac surgery (n  11).
ive-year follow-up results. Clinical follow-up was ob-
ained in 92% of living patients (100% complete five-year
ollow-up).
ORTALITY. In the CABG group, a total of 26 patients
ied during the five years of follow-up; 13 of these deaths
ccurred during the first 30 days after the procedure, and 13
dditional patients died during the rest of the five years of
ollow-up. Five of these deaths were non-cardiac in origin
pulmonary emphysema, stroke, renal insufficiency, and
rostate and lung cancer). In the PCI group, 16 patients
ied during the five years of follow-up, 7 during the first
ear, and 9 more between the first and fifth years of
ollow-up. Four of these deaths were non-cardiac in origin
renal insufficiency, lung cancer, pulmonary emphysema,
nd mesenteric infarction). There were no significant dif-
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August 16, 2005:582–8 Stents Versus CABG in Multi-Vessel Diseaseerences in mortality from all causes between the CABG
nd the PCI arms (11.5% vs. 7.1%, p  0.182).
The corresponding actuarial survival curves during the
ve years of follow-up for these two groups of patients also
howed a trend toward better outcomes with PCI compared
ith bypass surgery (92.8% vs. 88.4%, log-rank test, p 
.095) (Fig. 1).
The five-year mortality in diabetic patients with surgery
as 10.2% (4 of 39); with two-vessel disease, 10.6% (10 of
4); and with three-vessel disease, including left main
tenosis, 12.2% (16 of 131).
ON-FATAL MI. In the CABG group, 14 patients (6.2%)
ustained a new non-fatal Q-wave MI within the five years
f follow-up, with all of them occurring during the first
ear. In the PCI group, six patients (2.8%) sustained a new
on-fatal Q-wave MI within the five years of follow-up, five
uring the first year of follow-up. There were no significant
ifferences in the incidence of new non-fatal MI between
he PCI and CABG group (2.8% vs. 6.2%, respectively, p
.128). The corresponding actuarial survival curves with
reedom from non-fatal MI during the five years of
ollow-up for these two groups of patients showed no
ignificant differences between PCI and CABG (97.3% vs.
4%, log-rank test, p  0.159) (Fig. 2).
EPEAT REVASCULARIZATION PROCEDURES. A total of 64
atients (28.4%) in the PCI group and 17 patients (7.2%) in
he coronary bypass surgery group underwent a second
evascularization procedure (PTCA or CABG) during the
ntire follow-up period (p  0.0002). In the PCI arm,
6.6% occurred during the first year of follow-up. Most of
he repeat procedures performed in the PCI group either in
he first year or thereafter were new PCI procedures. Of
ote: only 19 patients in the PCI group crossed over to
ABG during the five years of follow-up (8.4%).
The corresponding actuarial survival curve with freedom
rom repeat revascularization procedures during the five
ears of follow-up were significantly better with coronary
ypass surgery than with PCI (92.4% vs. 71.5%, p 
.00001) (Fig. 3). The comparison in the number of repeatigure 1. Comparison of survival of patients treated with coronary artery
ypass grafting (CABG) versus percutaneous coronary intervention (PCI).
c
pevascularization procedures with our previously published
RACI I trial showed an improvement of late outcome
ith stents compared with balloon angioplasty (1,9). At five
ears, there was less incidence of repeat PTCA/CABG in
he ERACI II trial versus the three years follow-up of the
RACI I trial (28.4% vs. 37%, p  0.053). Furthermore,
he numbers of patients who required cross-over to surgery
as significantly lower in the ERACI II trial compared with
he ERACI I trial (8.4% vs. 22%, respectively, p  0.016).
NCIDENCE OF ANGINA. During the first year of follow-up,
he ERACI II trial patients assigned to CABG were more
requently free of angina than those assigned to PCI (92%
s. 84.5%, p  0.01); however, as shown in Figure 4, after
ew revascularization procedures were performed, the inci-
ence of angina was similar in the two groups. At the end
f the follow-up period, a similar number of patients in each
roup were asymptomatic or in Canadian class I angina
86% in PCI and 82% in CABG, p  0.916).
vent-free survival (MACE). The primary end point of
he study was “event-free survival” (freedom from death,
on-fatal MI and repeat revascularization (PCI or CABG),
nd stroke). At one year of follow-up, we reported no
ignificant differences between the two strategies of revas-
ularization (11).
In the present study, during the five years of follow-up,
8 patients in the PCI group and 53 patients in the CABG
roup suffered one or more cardiac events (Fig. 5); thus, the
orresponding actuarial survival curve of freedom from
ACE showed a better outcome with CABG (76.4% vs.
5.3%, p  0.019). This difference was due solely to the
igure 2. Comparison of non-fatal myocardial infarction of patients
reated with coronary artery bypass grafting (CABG) versus percutaneous
oronary intervention (PCI).
igure 3. Comparison of repeat revascularization procedures (percutaneous
oronary intervention [PCI] or coronary artery bypass grafting [CABG]) of
atients treated with CABG (square symbols) versus PCI (round symbols).
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Stents Versus CABG in Multi-Vessel Disease August 16, 2005:582–8resence of a greater incidence of repeat revascularization
rocedures in the PCI arm.
ong-term follow-up costs. During the first year of
ollow-up, both strategies of revascularization had similar
ost. Cost included the cost of initial procedure, hospital
harges, procedural resources (PTCA devices others than
alloon, medications other than glycoprotein inhibitors),
nd professional fees.
During the five years of follow-up, the number of patients
equiring new revascularization procedures between the first
nd fifth year were still significantly higher with PCI,
esulting in an additional cost, between one- and five-year
ollow-up in the PCI group, of $236,000 to the overall cost
t one-year (14 PCI and 9 CABG). In contrast, there was
n additional one- to five-year follow-up cost in the CABG
roup of $45,000 (four PCI and one redo-CABG).
Thus, at the end of the five years of follow-up, compar-
son of overall cost of the two strategies of revascularization
howed a trend toward higher cost with PCI ($3,056,615 in
CI and $2,556,500 in CABG, p  0.069). Thus, the
ost-per-patient was significantly higher with stent therapy
$13,584 vs. $11,362 for the PCI and the CABG groups
espectively, p  0.04).
ISCUSSION
n the present study, patients with multi-vessel disease and
high prevalence of unstable angina (91%) included in the
RACI II trial, treated initially with PCI with liberal use of
are metal stents, had similar survival and incidence of
on-fatal MI at five years of follow-up when compared with
hose initially treated with CABG. Even though survival
as higher in PCI-treated patients, that difference was not
ignificant at five years of follow-up.
The findings of this long-term follow-up changed our
reviously reported safety-benefit findings at short-term
utcome with PCI randomized patients. The incidence of
epeat procedures and angina was significantly higher with
tents; however, at the end of the follow-up, a similar
umber of patients in each group were asymptomatic or
igure 4. Comparison of freedom from angina between patients treated
ith coronary artery bypass grafting (solid bars) versus percutaneous
oronary intervention (gray bars).ith class I angina, and only 8.4% of the patients in the PCI
b
troup crossed over to surgery during the entire follow-up
eriod.
The end point of freedom from MACE showed fewer
vents with surgery, due to the greater numbers of patients in
he PCI group requiring new revascularization procedures.
Overall costs of both procedures (according to the mod-
les of practices of the Social Security System of Argentina)
howed that current PCI resources in this group of patients
ad a trend for higher costs than CABG at the end of the
ve years of follow-up.
We previously published (11) the 30-day and one-year
utcomes of the ERACI II trial. The hospital results of this
rial showed lower in-hospital death and MI in those
atients treated with stents when they had unstable angina
r post-AMI angina at the time of randomization. In
greement with these findings, others trials and registries
ave reported higher hospital mortality with surgery in
hose patients with refractory unstable angina or post-MI
ngina (19–27).
Even though other randomized comparisons between
tents and surgery, such as the ARTS (10) and the Stent or
urgery trials (12), reported a lower hospital mortality with
urgery than the ERACI II trial, the baseline clinical and
ngiographic characteristics of these two studies differ from
ur trial. These differences in baseline patient populations
ould explain these results. In fact, when similar cohorts of
atients of the ERACI II and the ARTS trials were
ompared, the hospital and one-year results from the two
rials were identical (23). More recently, a randomized
omparison between CABG and PCI (the Angina With
xtremely Serious Operative Mortality Evaluation study)
howed a 5% incidence of 30-day mortality with surgery in
atients with refractory myocardial ischemia (13,21).
It has been well established that the use of coronary bare
etal stents, compared with balloon angioplasty, has been
ssociated with both lower acute complications and reste-
osis (16,24,25). Consequently, we witnessed a significant
hange in the incidence of repeat revascularization proce-
ures at five years of follow-up with the use of bare metal
tents. Compared with the ERACI I trial, stent use in the
RACI II trial reduced the gap between PCI and CABG
y 24%. In contrast, requirements of new revascularization
rocedures with surgery remained stable during the last
igure 5. Comparison of freedom from major adverse cardiovascular
vents (alive and free of non-fatal myocardial infarction or stroke or repeat
evascularization procedures) of patients treated with coronary artery
ypass grafting (square symbols) versus percutaneous coronary interven-
ion (round symbols).
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August 16, 2005:582–8 Stents Versus CABG in Multi-Vessel Diseaseecade (6.3 vs. 6.2% in the ERACI I and ERACI II trials,
espectively) (1).
Furthermore, patients in the PCI arm who needed to
ross over to surgery also were significantly reduced in stent
ra. A large meta-analysis from eight randomized studies
omparing balloon angioplasty with bypass surgery (8), at
.5 years of follow-up, showed that 18% of patients with
alloons needed to cross over to CABG. This value was
igher than the 8.4% showed by our study with the liberal
se of stents in the PCI arm. And the cross-over to CABG
ate was 22% at three years in the balloon angioplasty group
f the ERACI I trial.
Both lower acute hospital complications and restenosis
mproved the long-term outcomes in those patients treated
ith bare metal stents compared with old balloon PTCA
echniques. Therefore, freedom from MACE at five years of
ollow-up in the ERACI II trial was better when compared
ith the three-year incidence of MACE of the ERACI I
rial (1,9) ( 65% vs. 49%, respectively, p  0.02).
In accordance with the number of repeat revascularization
rocedures, the incidence of angina during the entire
ollow-up period was significantly better with bypass sur-
ery, reflecting restenosis or incomplete revascularization in
he coronary stent group (14,26,27). This difference is
ttenuated during later follow-up, however, so by the end of
he five years of follow-up, the prevalence of angina was
imilar in the two groups as a consequence of a higher rate
f additional coronary revascularization procedures during
he follow-up in the PCI patients.
In the past, initial and mid-term follow-up of percutane-
us revascularization techniques was less expensive than the
onventional coronary bypass surgery with arterial or vein
raft conduit (1–9); nevertheless, this initial advantage
eclined over the long-term follow-up.
In the present study, the liberal use of stents during the
CI procedure increased the cost of percutaneous interven-
ions significantly in Argentina compared with several years
go (1,9). In contrast, the cost of conventional coronary
ypass surgery remained stable. In comparison with the
RACI I trial, which enrolled patients at the end of 1980,
he ERACI II trial, performed in 1988, was more expensive.
hus, at five years of follow-up, our current study showed
hat percutaneous interventions had a trend toward higher
osts, compared with conventional surgery. The relatively
igh proportion of glycoprotein inhibitors used in this study
n the PCI arm (28%), due to the large number of patients
reated with acute coronary syndromes, also helped explain
he increase of cost in the stent group. We should remem-
er, however, that cost-effectiveness of either revascularization
rocedure requires consideration of acute and long-term safety
nd of efficacy demonstrated for each revascularization pro-
edure in different subsets of patients.
tudy limitations. As previously cited (11), our study
nvolved a large cohort of patients with unstable coronary
yndromes at high risk for in-hospital morbidity and
ortality.Because the differences in major events largely occurred
uring the hospital period and mainly in patients with more
evere unstable angina, these results could change if the
linical profiles of the patients treated were different (21). In
act, these differences in our study were not reported
reviously in those patients with stable angina.
The numbers of repeat revascularization procedures at
hree years in the PCI group could be associated with the
tent design used in our study (GRII, Cook Cardiology Inc.,
loomington, Indiana) that was reported higher than other
tent designs (28). Furthermore, a significant reduction of
estenosis in the new era of drug-eluting stents (29–31) has
ecently been demonstrated and could change the long-term
utcome and efficacy of percutaneous interventions. The
ost-effectiveness of these percutaneous techniques com-
ared with conventional or mid-CABG will need prompt
ew comparisons.
onclusions. This multicenter randomized study compar-
ng stent therapy with coronary bypass surgery demonstrates
hat in patients with multi-vessel coronary artery disease
ho have had lower 30-day mortality and incidence of MI
hen treated with routine bare metal stent therapy, at five
ears of follow-up, the two groups did not have significant
ifferences either in survival or freedom from non-fatal MI.
ompared with CABG patients, however, patients with
ulti-vessel disease treated with PCI continue to have an
ncreased incidence of repeat revascularization procedures at
ollow-up.
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PPENDIX
or the ERACI II five-year follow-up study organization
nd participants, please see the online version of this article.
